[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 242,072
  • Shares Outstanding, K 57,912
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -120 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.82

Options Overview Details

View History
  • Implied Volatility 289.38% (+14.76%)
  • Historical Volatility 318.72%
  • IV Percentile 82%
  • IV Rank 57.59%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 13) 1.57 (38.45%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 2,792
  • Volume Avg (30-Day) 11,176
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 203,561
  • Open Int (30-Day) 144,493
  • Expected Range 2.52 to 5.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 5
  • High Estimate $-0.47
  • Low Estimate $-0.63
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) -1.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +38.18%
on 07/30/26
23.03 -82.24%
on 07/08/26
-18.13 (-81.59%)
since 07/07/26
3-Month
2.96 +38.18%
on 07/30/26
32.55 -87.43%
on 05/11/26
-29.85 (-87.95%)
since 05/07/26
52-Week
2.96 +38.18%
on 07/30/26
40.37 -89.87%
on 12/03/25
-3.98 (-49.32%)
since 08/07/25

Most Recent Stories

More News
Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and Lead Plaintiff Deadline on September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 63.17 (+0.27%)
CAPR : 4.09 (-2.15%)
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 7, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

CAPR : 4.09 (-2.15%)
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 63.17 (+0.27%)
CAPR : 4.09 (-2.15%)
INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - CAPR

SAN DIEGO , Aug. 7, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December...

CAPR : 4.09 (-2.15%)
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Seek Leadership in a Securities Fraud Lawsuit by September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 63.17 (+0.27%)
CAPR : 4.09 (-2.15%)
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

SAN FRANCISCO , Aug. 6, 2026 /PRNewswire/ -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR)  who suffered substantial losses to submit your losses now...

CAPR : 4.09 (-2.15%)
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , Aug. 6, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith  announces that investors with substantial losses have opportunity to lead the securities fraud class action...

CAPR : 4.09 (-2.15%)
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor...

CAPR : 4.09 (-2.15%)
CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

A securities class action alleges Capricor Therapeutics failed to disclose that it changed the pre-specified statistical analysis plan for its Phase 3 HOPE-3 trial without FDA agreement, leaving results...

CAPR : 4.09 (-2.15%)
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR

A securities class action alleges Capricor Therapeutics told investors its Phase 3 HOPE-3 results were statistically significant while allegedly omitting that the final statistical analysis...

CAPR : 4.09 (-2.15%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 4.93
1st Resistance Point 4.51
Last Price 4.09
1st Support Level 3.86
2nd Support Level 3.63
3rd Support Level 3.21

See More

52-Week High 40.37
Fibonacci 61.8% 26.08
Fibonacci 50% 21.66
Fibonacci 38.2% 17.25
Last Price 4.09
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.